ViiV Healthcare to present data for its next generation of ultra ...
WEBFeb 28, 2024 · GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as …
ViiV Healthcare announces U.S. FDA approval of Dovato ...
WEBDURHAM, N.C., April 08, 2024 -- ( BUSINESS WIRE )--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as …
ViiV Healthcare Announces Interim Data at CROI Indicating ...
WEBLONDON, March 06, 2024--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced …
ViiV Healthcare presents phase I clinical trial findings of a ...
WEBLONDON, March 04, 2024 -- ( BUSINESS WIRE )--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today …
ViiV Healthcare and Medicines Patent Pool Announce Major ...
WEB30 April 2024. 12:42. Expand. ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, together with the Medicines …
カボテグラビル超長時間作用型製剤の第1相臨床試験の結果に ...
WEBMar 7, 2024 · 塩野義製薬株式会社（本社：大阪市中央区、代表取締役会長兼社長CEO：手代木 功、以下「塩野義製薬」または「当社」）は、当社がGlaxoSmithKline plc.およ …
GSKとヴィーブヘルスケア、業界をリードする感染症 ...
WEBOct 19, 2023 · GSKは、サイエンス、テクノロジー、人財を結集し、力を合わせて病に先手を打つことを存在意義とするバイオ医薬品のグローバルリーダーです。 詳細情報は …
ViiV Healthcare reports data from injectable HIV treatment trial
WEBFebruary 22, 2024. The trial of the long-acting injectable antiretroviral treatment is underway at 31 sites in the US. Credit: LookerStudio / Shutterstock.com. ViiV Healthcare has …
GSK’s ViiV Healthcare to Share Latest Advances in HIV ...
WEB(PRESS RELEASE) LONDON, 19-Oct-2023 — / EuropaWire / — GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority …
ViiV Healthcare presents phase I clinical trial findings of a ...
WEB04 March 2024. Issued: London, UK. For media and investors only. ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable …
- Some results have been removed
Skip to content
